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This work reports the preparation of tablets by direct compression of sodium alendronate-loaded 
microparticles, using pullulan as filler. The tableting properties of pullulan were compared with those of 
microcrystalline cellulose and lactose. Pullulan tablets showed low variations in average weight, thickness 
and drug content. Moreover, these tablets exhibited a higher hardness compared to the other excipients. 
In vitro release studies showed that only pullulan was capable to maintain gastroresistance and release 
properties of microparticles, due to its ability to protect particles against damage caused by compression 
force. Thus, pullulan was considered an advantageous excipient to prepare tableted microparticles.
Uniterms: Pullulan. Excipients. Microparticulate tablets. Sodium alendronate.
Neste trabalho relata-se a preparação de comprimidos pela compressão direta de micropartículas contendo 
alendronato de sódio, utilizando o pullulan como diluente. As propriedades dos comprimidos de pullulan 
foram comparadas com as de comprimidos de celulose microcristalina e de lactose. Os comprimidos de 
pullulan mostraram baixa variação no peso médio, espessura e teor. Por outro lado, estes apresentaram 
altos valores de dureza comparados aos preparados com os outros excipientes. Através dos estudos de 
liberação in vitro pode-se observar que apenas o pullulan foi capaz de manter a gastrorresistência e as 
propriedades de liberação das micropartículas, o que se deve à sua capacidade de proteger as partículas 
do dano causado pela força de compressão. Dessa forma, o pullulan foi considerado um excipiente 
vantajoso para a preparação de comprimidos microparticulados.
Unitermos: Pullulan. Excipientes. Comprimidos microparticulados. Alendronato de sódio.
INTRODUCTION
Polymeric microparticles are promising carriers for 
oral administration of therapeutic drugs mainly due to their 
ability to give a more uniform distribution of the drug in the 
gastrointestinal tract, thus increasing bioavailability and 
reducing mucosal toxicity (Freiberg, Zhu, 2004; Varde, 
Pack, 2004). A previous study reported the development 
of gastroresistant microparticles made of Eudragit® S100 
in order to reduce mucosal damage associated with sodium 
alendronate, an antiosteoporotic drug (Cruz et al., 2010). 
Although Eudragit® S100 microparticles can be considered 
a promising alternative for oral administration of sodium 
alendronate, microparticles are rarely used directly in their 
powder form, thus, the development of a final formulation 
is required.
Tablets are the most popular form of solid dosage, 
because they are easily dosed, produced and are stable 
(Jivraj, Martini, Thomson, 2000; Wening, Breitkreutz, 
2011). Tablets can be divided into monolithic (single-unit 
FIGURE 1 - Chemical structure of sodium alendronate.
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dosage form) and multiparticulate (multiple-units dosage 
forms) systems. In the former, there is only one release 
unit in which the drug is not divided. On the other hand, 
in a multiparticulate system the drug is divided in subunits 
of release, which can be granules, pellets, minitablets or 
microparticles. These subunits, in turn, were compressed 
into tablets by direct compression using tableting excipients 
(Pezzini, Silva, Ferraz, 2007). However, compressing 
microparticles into tablets is a challenge due to the fact 
that the particle must withstand the compression force in 
order to avoid its rupture or deformation with consequent 
increase in dissolution rates (Torrado, Augsburger, 1994). 
In this sense, the selection of a suitable excipient can be 
considered an interesting approach to form multiple unit 
tablets. In general, materials that deform plastically, such 
as microcrystalline cellulose, give the best protective 
effect (Torrado, Augsburger, 1994; Beckert, Lehmann, 
Schmidt, 1996; Velasquez et al., 2014). Moreover, an ideal 
excipient should result in hard and disintegrating tablets at 
low compression forces and should not affect drug release 
(Bodmeier, 1997).
Natural polysaccharides are widely employed as 
pharmaceutical excipients because of their low toxicity, 
availability and low cost (Ngwuluka et al., 2010). Pullulan, 
a neutral polysaccharide of microbiological origin, has 
attracted much attention in the last few years in view of its 
potential for pharmaceutical and biomedical applications 
(Rekha, Sharma, 2007). This exopolysaccharide is 
produced from starch by Aureobasidium pullulans and 
is comprised of maltotriose repeating units linked by 
a(1→6) bonds. Pullulan is considered a promising 
biomaterial mainly due to its non-toxic, biodegradable 
and bioadhesive properties (Cheng, Demirci, Catchmark, 
2011). In the pharmaceutical field, pullulan is being used 
as a plasma expander and in the composition of oral care 
products due to its ability to form colorless, transparent 
and edible films. In the formulation of oral solid dosage 
forms, pullulan has been reported to prepare vegetarian 
capsule shells and act as a coating agent to prevent tablet 
deterioration, increase mechanical resistance, reduce 
cracking and color deterioration and improve gloss 
(Cheng, Demirci, Catchmark, 2011). Up to now, there 
is no report on the preparation of tableted microparticles 
with pullulan.
Taking all of this into account, the aim of the present 
study was to prepare tablets by direct compression of 
sodium alendronate-loaded Eudragit® S100 microparticles 
using pullulan as a filler and to evaluate the gastroresistance, 
drug release profile and morphology of the microparticles 
after compression. The tableting properties of pullulan 
were compared with those of two widely used excipients, 
microcrystalline cellulose and lactose.
MATERIAL AND METHODS
Material
Monosodium alendronate trihydrate was purchased 
from Pharma Nostra (São Paulo, Brazil). Pullulan was 
generously donated by Corn Products (São Paulo, Brazil) 
and Eudragit® S100 (Poly(methacrylic acid-co-methyl 
methacrylate) 1:2) from Degussa was donated by Almapal 
(São Paulo, Brazil). Lactose and stearate magnesium were 
obtained from Henrifarma (São Paulo, Brazil). Avicel® 
FIGURE 2 - Chemical structure of pullulan.
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PH101 (Microcrystalline cellulose) was a gift from FMC 
corporation (Philadelphia, USA). o-Phtalaldehyde was 
purchased from Sigma-Aldrich (São Paulo, Brazil) and 
2-mercaptoethanol was acquired from Acros Organics 
(Geel, Belgium). All other solvents and reagents were of 
analytical grade and were used as received.
Preparation and characterization of 
microparticles
As previously described (Cruz et al., 2010), 
alendronate-loaded microparticles (AMP) were prepared 
by the spray-drying technique. Briefly, an alkaline solution 
(0.05 mol/L NaOH) of Eudragit® S100 (16.0 g/L) was 
prepared under magnetic stirring at 50°C. Alendronate 
(4.0 g/L) was added to the solution before spray-drying 
(MSD 1.0, LabMaq, Brazil). Operational conditions 
were the following: feed rate of 0.33 L/h, air flow rate 
of 70 nL/h, atomizing air pressure of 3.0 kgf/cm, inlet 
temperature of 150 °C and nozzle diameter of 1.2 mm. 
The yield of the process was calculated by the ratio of 
the experimental weight and the sum of the weights of all 
components, discounting the water content.
Encapsulation efficiency was determined by 
spectrophotometry using o-phtalaldehyde (OPA) as a 
derivatizing agent (Cruz et al., 2009). A stock standard 
solution of alendronate was prepared by accurately weighing 
and dissolving 12.5 mg of the drug in 25 mL of 0.2 mol/L 
NaOH in a volumetric flask. The derivatizing solution 
consisted of 50 mg of OPA and 250 mL of mercaptoethanol 
diluted with 50 mL of 0.05 mol/L NaOH in a volumetric 
flask. Six standard solutions with different concentrations 
of alendronate (10-60 mg/mL) were then prepared by adding 
aliquots of the stock alendronate solution and derivatizing 
them with 4 mL of the OPA reagent. The volume was 
completed to 50 mL with 0.2 mol/L NaOH. The absorbances 
were measured at 333 nm.
Particle sizes and size distribution (Span) were 
evaluated by laser diffraction using a Mastersizer 2000 
device (Malvern, United Kingdom) equipped with a 
Sirocco dry disperser at dispersing pressure of 1 bar.
Moisture content was assayed using an infrared 
drying equipment IV 2500 (Gehaka, Brazil) kept at 115 °C 
until constant weight.
Preparation and characterization of tableted 
microparticles
Tablets with theoretical mean weight of 750 mg were 
prepared by direct compression of AMP and excipients 
(Sinka et al., 2009). Firstly, an amount of microparticles 
corresponding to 91.35 mg of alendronate was mixed with 
pullulan (or microcrystalline cellulose or lactose) and 
the lubricant (magnesium stearate) in a glass mortar. The 
percent composition was 77% AMP, 22.25% filler, and 
0.75% lubricant. The formulations were named as T1, T2 
and T3 when pullulan, microcrystalline cellulose or lactose 
were used as diluents, respectively.
Subsequently, an exact amount of the powder 
mixture was filled in a die using a little pressure. 
Hydraulic pressure (300 kgf/cm2) was then used to form 
flat faced tablets of 13 mm diameter and 4 mm thickness 
in an eccentric compression machine (Neuberger Press, 
Brazil). The weight variation was determined by weighing 
individually 10 tablets in an analytical balance AY220 
(Shimadzu, Japan).
Thickness was evaluated using a manual caliper 
(n=10). The value of mean hardness (n=10) was obtained 
by using a portable hardness tester (Off Tec Galileo, 
Brazil).
To determine the uniformity of content (n=3), each 
tablet was pulverized in a glass mortar and the drug was 
extracted by diluting (0.2 mol/L NaOH; 50 mL) and 
sonicating (30 min) the powder in a volumetric flask. 
After filtration and dilution (0.2 mol/L NaOH; 50 mL), 
an aliquot was assayed spectrophotometrically at 333 nm 
after derivatization with OPA as described above.
For in vitro release profiles (n=3), experiments were 
carried out in a dissolution apparatus PTW II (Pharma Test, 
Brazil): basket, rotation speed of 100 rpm at 37 °C (Cruz 
et al., 2010). Gastroresistance was evaluated during 120 
minutes in 900 mL 0.1 mol/L HCl (pH 1.2). In its turn, the 
dissolution test was performed in 900 mL phosphate buffer 
(pH 6.8) during 240 minutes. At specified time intervals, 
1 mL was withdrawn and immediately replaced by the 
medium. The percent of alendronate released was assayed 
spectrophotometrically after dervatization (l=333 nm) as 
described above.
Drug release profiles were analyzed by the first 
order equation, Qt/Q∞=1-[e-kt], and the Korsmeyer-
Peppas model, Qt/Q∞=a.tn. In these equations, Qt/Q∞ is the 
fractional drug release, k is the rate constant, a is a constant 
incorporating structural and geometric characteristics of 
the carrier, and n is the release exponent, indicative of the 
drug release mechanism. For systems presenting spherical 
geometry, n=0.43 corresponds to Fickian diffusion, n 
values between 0.43 and 0.85 imply anomalous transport, 
while n≥0.85 indicates case II transport (Korsmeyer et 
al., 1983).
SEM microphotographs of tablet cross-sections 
were obtained by breaking the units into half. The 
fractured parts of the tablet were gold sputtered (Desk II 
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Gold Sputter, Denton Vacuum, USA) and subsequently 
analyzed using an accelerating voltage of 10 kv (Scanning 
microscope JSM-6360, Jeol, Japan).
Statistical analysis
The data were analyzed by one way or two way 
analysis of variance (ANOVA). The Tukey test was used 
for multiple comparisons. A p-value < 0.05 was considered 
to be statistically significant (GraphPad Prism software, 
U.S.A).
RESULTS AND DISCUSSION
AMP formulation was obtained with a yield of 
43.19 ± 1.13%, encapsulation efficiency of 87.75 ± 0.31%, 
moisture content of 5.9%, mean diameter of 3.65 mm 
with narrow size distribution (Span of 1.43). The formed 
microparticles were tableted by direct compression using 
pullulan (formulation T1). For comparison, tableted 
microparticles were also produced with traditional fillers, 
such as microcrystalline cellulose (formulation T2) and 
lactose (formulation T3) due to their excellent properties 
as filler-binders (Jivraj, Martini, Thomson, 2000). The 
properties of tablets containing AMP are shown in Table I.
Tablets prepared with pullulan (T1) showed low 
variations in the characteristics studied, as observed 
for the formulations T2 and T3, which means that the 
compression process was consistent. Comparing the three 
tablet formulations, there were no significant differences 
in average weight and thickness (p>0.05). On the other 
hand, hardness, which corresponds to the tablet breaking 
force, was significantly different among all formulations 
(p<0.05). Existing studies in the literature show that 
the use of different types of diluents may influence the 
hardness of tablets, due to compaction properties of each 
raw material (Holgado et al., 1995). The results clearly 
show that pullulan has excellent binding properties upon 
compaction, producing more cohesive and compact 
tablets in comparison to the other adjuvants evaluated 
(microcrystalline cellulose and lactose) by employing the 
same proportion in the formulation and applying the same 
compression force. It should be noted that in a previous 
test, alendronate-loaded Eudragit® S100 microparticles, 
without any excipient, were not able to form tablets 
by direct compression (data not showed) due to their 
poor binding properties. Thus, pullulan imparts suitable 
hardness to the tablets without addition of a specific binder 
in the formulation, probably as a result of its adhesive and 
cohesive properties. As regards uniformity of content, the 
tablets prepared with pullulan had also a content percent 
close to the theoretical value (Table I).
With respect to the evaluation of gastroresistance, 
tableted AMP was submitted to a simulated gastric 
fluid (Figure 3). Within 120 min, 24.5 ± 0.72% and 
27.6 ± 1.18% of alendronate were released from 
microcrystalline cellulose and lactose tablets, respectively, 
whereas only 6.7 ± 0.30% of the drug was released 
from pullulan tablets at the same time. In a previous 
study (Cruz et al., 2010), it has been shown that about 
5% of alendronate was released from Eudragit® S100 
microparticles under the same experimental conditions, 
which is considered an adequate result since no more than 
10% of the drug should be released from a gastroresistant 
formulation in 2 h of experiment (USP, 2008). In addition, 
both results of gastroresistance (untableted and tableted 
microparticles) are statistically different (p=0.0034). 
TABLE I - Properties of tableted microparticles
T1 T2 T3
Average weight (mg) 758 ± 13 753 ± 23 750 ± 13
Thickness (cm) 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
Hardness (kgf) 13.5 ± 0.5 8.0 ± 0.5 4.8 ± 0.3
Uniformity of content (%) 99.0 ± 0.5 104.7 ± 0.7 103.2 ± 2.7
FIGURE 3 - In vitro release profiles of T1, T2 and T3 
formulations in 0.1 mol/L HCl pH 1.2.
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FIGURE 4 - SEM photomicrographs of microparticles (A) and cross-sections of tableted microparticles T1 (B), T2 (C) and T3 (D).
Comparing the results obtained for untableted AMP (Cruz 
et al., 2010) and tableted AMP, only pullulan was capable 
of maintaining the gastroresistance of the microparticulate 
formulation, which could be explained by its ability 
to protect the particles against damage caused by the 
compression force. To corroborate this hypothesis, SEM 
analyzes of tablet cross-sections were performed. By 
comparing the photomicrograph of T1 tablet (Figure 4B) 
with that obtained for AMP (Figure 4A), it was possible 
to visualize the presence of individual particles with the 
same morphology observed in Figure 4A, which indicates 
that AMP remain intact after compression. On the other 
hand, tablets produced with microcrystalline cellulose 
and lactose showed few microparticles, suggesting that 
a great part of these structures has suffered rupture or 
fracture upon compression in samples T2 and T3 (Figure 
4C and 4D).
Tablets were also evaluated for their dissolution 
profiles in simulated intestinal fluid. In Figure 5 one 
may observe that the release profile of alendronate from 
pullulan tablets (T1) is significantly slower than T2 and 
T3 tablets (p<0.05). In the first hour, approximately 81% 
and 91% of alendronate were released from T2 and T3 
formulations, respectively. On the other hand, 55% of 
the drug was released from T1 tablets. This data is very 
similar to the result obtained for AMP in a previous 
study where 56% of alendronate was released from 
untableted AMP within the same time and under the same 
experimental conditions (Cruz et al., 2010). The similarity 
may be explained by the fact that microparticles tableted 
in the presence of pullulan remained intact and, hence, 
retained their release properties, which corroborates the 
gastroresistance result and SEM analysis. On the other 
hand, microcrystalline cellulose and lactose were not 
suitable for tableting AMP because the release properties 
were not the same observed for untableted AMP. Tablets 
containing multiples units should disintegrate into their 
subunits of release and drug release should not be affected 
by the compression. It is important to mention that all 
tablets disintegrated during the experiment.
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To calculate the rate constant associated to drug 
release, the dissolution data were fitted to first order 
equation. Table II shows that T1 tablets presented the 
lowest value of rate constant and, hence, the highest half-
life, confirming the slower alendronate releases from this 
formulation. In addition, T1 tablets presents the best data 
fitting to the first order equation (r>0.99).
The data were also fitted to the Korsmeyer-Peppas 
model in order to investigate the drug release mechanism. 
Taking into account the values obtained for the release 
exponent n, alendronate was released from pullulan 
tablets by anomalous transport, i.e., the drug release was 
dependent on the swelling of the system followed by 
drug diffusion. On the other hand, the Korsmeyer-Peppas 
model indicated Fickian diffusion as the main mechanism 
of alendronate release from T2 and T3 tablets. This result 
is consistent with the hypothesis that indicates rupture of 
the microparticles in T2 and T3 formulations because the 
swelling of the system did not occur in this case.
TABLE II - Parameters derived from the mathematical modeling of alendronate release profile from tableted microparticles
Model/Parameters T1 T2 T3
First order
R 0.9902 ± 0.0008 0.9886 ± 0.0007 0.9747 ± 0.0030
k (min-1) 0.0138 ± 0.0002 0.0303 ± 0.0007 0.0389 ± 0.0016
t½ (min) 50.2 22.9 17.8
Korsmeyer-Peppas T1 T2 T3
R 0.9949 ± 0.0034 0.9933 ± 0.0015 0.9882 ± 0.0030
A 0.0175 ± 0.0010 0.1470 ± 0.0080 0.1810 ± 0.0109
N 0.8415 ± 0.0112 0.3949 ± 0.0105 0.3647 ± 0.0138
FIGURE 5 - Alendronate release profiles from T1, T2 and T3 
tablets in phosphate buffer solution pH 6.8.
CONCLUSION
The results of this study suggest that pullulan is a 
useful excipient to prepare tableted microparticles, since 
it presented excellent filler-binder properties. T1 tablets 
exhibited superior technical qualities compared with the 
T2 and T3 formulations. The tablets manufactured with 
pullulan had good content uniformity, as well as thickness, 
low variation in average weight and suitable hardness 
with no addition of a specific binder. The compression 
of microparticles was found to not affect drug release, 
which indicates that the tablet behaves as a multiple unit 
dosage form. This may be due to the protective effect of 
pullulan and the rapid disintegration of the tablets into 
microparticles observed during the release study at pH 6.8. 
The tableted microparticles prepared in this study have the 
potential to give a more predictable in vivo drug release 
and to decrease the gastrointestinal irritation caused by 
the oral administration of sodium alendronate. Tablets T1 
have the potential to give a more predictable in vivo drug 
release and were considered a promising formulation for 
sodium alendronate oral administration.
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